ModAstera and Wellgen Medical are partnering to build AI screening models for cancer cytology, combining FDA-cleared tomographic imaging, clinical datasets, and rapid medical AI deployment.
By ModAstera
28 Apr 2026
Tokyo, Japan / Kaohsiung, Taiwan. April 28, 2026
ModAstera Inc. and Wellgen Medical CO., LTD today announced a strategic intellectual property collaboration to develop AI-powered screening models for cancer cytology. The partnership combines Wellgen's FDA-cleared tomographic imaging hardware and clinical datasets with ModAstera's medical AI development platform to address one of oncology's most persistent bottlenecks: the accurate, timely detection of metastatic cancer cells in body fluid specimens.
Cytopathology, the analysis of cancer cells from body fluids such as pleural effusions and ascitic fluid, sits on the frontline of metastatic cancer detection. Yet the field faces two compounding challenges.
First, the global shortage of pathologists is accelerating. The United States is projected to face a deficit of 5,000 pathologists by 2030, while Japan operates with just 1.4 pathologists per 100,000 people, roughly one-fifth of the U.S. ratio.
Second, diagnostic sensitivity for metastatic cancer in fluid cytology still ranges from only 32% to 77% depending on cancer type and method. That leaves a significant share of Stage 4 cases undetected at the point where earlier intervention could matter most.
The tools available to cytologists have not kept pace with the complexity of the problem. Whole-slide scanners designed for flat histology sections struggle in cytology, where cell accumulations stack in three dimensions and can hide individual cancer cells behind clusters and debris. AI cannot fix what the image does not show.
ModAstera Inc. is a Tokyo-based medical AI infrastructure company building the tools and models that accelerate clinical AI from concept to deployment. Its flagship platform, MAEA (Medical AI Engineering Agent), is an end-to-end development and MLOps environment engineered specifically for healthcare, compressing AI model development timelines from the industry standard of 18–24 months to as little as 30–60 days.
ModAstera is backed by Antler Japan and is a member of the Qualcomm AI Innovators Program APAC.
Wellgen Medical is a medical device company specialising in next-generation digital cytology. Wellgen developed CytoScope, the world's first scanner purpose-built for cytology specimens, alongside CellDetect, its FDA-listed AI analysis software.
Wellgen's hardware and software are registered with the U.S. FDA and certified by Japan's PMDA, with active deployments across six hospitals in Taiwan and a demonstration site at Johns Hopkins in the United States. Wellgen's open dataset has also been used in AI research challenges hosted by the University of Chicago's Nightingale Open Science platform.
Under the joint agreement, the companies will co-develop and validate AI screening models for serous fluid cytology, integrated directly into Wellgen's CytoScope workflow. Pre-screened images will surface suspicious fields of view for pathologist review, reducing per-case screening time and creating a foundation for full telepathology deployment.
This collaboration reflects a shared belief that better imaging infrastructure and faster medical AI development pipelines can unlock a new standard for cytology diagnostics.
For partnerships and enquiries, please contact us through the contact page.
AutoML can help manufacturers move faster from factory data to candidate models, but deployable manufacturing AI still depends on data quality, process context, integration, monitoring, cybersecurity, and operational ownership.
Automated ML can speed up medical AI development, but deployable healthcare models still depend on clear clinical tasks, data quality, validation, workflow integration, monitoring, and governance.
ModAstera and Wellgen Medical are partnering to build AI screening models for cancer cytology, combining FDA-cleared tomographic imaging, clinical datasets, and rapid medical AI deployment.
